NCT01734239View on ClinicalTrials.gov

A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)

PHASE3CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

June 3, 2013

Primary Completion Date

October 22, 2013

Study Completion Date

October 22, 2013

Conditions
Pneumococcal Disease
Interventions
BIOLOGICAL

Pneumovax™ 23

Vaccine contains 25 µg of each of the 23 pneumococcal polysaccharides serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01734239 - A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018) | Biotech Hunter | Biotech Hunter